Abstract 19309: Use of Antithrombotic Therapy and 1-Year Outcome in Patients in Patients With Congestive Heart Failure and Impaired Ejection Fraction in Clinical Practice - Results of the Prospective EVITA-HF Registry
Background: The optimal antithrombotic therapy in patients with congestive therapy still has to defined. Therefore we analysed the data of large registry to investgate the use of different antithrombotic therapies in clinical practice.
Methods: The EVITA-HF registry prospectively enrolled 4260 patients with congestive heart failure and a left ventricular ejection fraction < 40 % in 25 centers. Patients were followed for at least 1 year. For this analysis we divided patients into 5 groups according to their antithrombotic therapy at discharge: no, single antiplatelet, dual antiplatelet, oral anticoagulation, oral anticoagilation + antiplatelet therapy.
Results: The baseline characteristics and 1-year events are given in the table.
Conclusion: There is an underuse of anticoagulation in patients with congestive heart failure and atrial fibrillation, while there was no clear indication for oral anticoagulation in about 1/3 of patients. Therefore guidelines are often no followed in clinical practice. Mortality is high regardless of the antithrombotic strategy.
Author Disclosures: U. Zeymer: None. W. von Scheidt: None. C. Zugck: None. M. Pauschinger: None. M. Hochadel: None. J. Senges: None.
- © 2016 by American Heart Association, Inc.